News Website

NRG-GY018 at ASCO 2026: Pembrolizumab Plus Chemotherapy Sustains Overall Survival Benefit in Advanced Endometrial Cancer - Oncodaily

NRG-GY018 at ASCO 2026: Pembrolizumab Plus Chemotherapy Sustains Overall Survival Benefit in Advanced Endometrial Cancer Oncodaily

Published: June 3, 2026, 3:15 a.m.

Read Full Article

Pembrolizumab Plus Chemotherapy Shows Sustained Survival in Advanced EC - CancerNetwork

Pembrolizumab Plus Chemotherapy Shows Sustained Survival in Advanced EC CancerNetwork

Published: May 30, 2026, 12:40 a.m.

Read Full Article

Pembrolizumab Plus Chemotherapy Shows Long-Term OS Benefit in Advanced/Recurrent Endometrial Cancer - OncLive

Pembrolizumab Plus Chemotherapy Shows Long-Term OS Benefit in Advanced/Recurrent Endometrial Cancer OncLive

Published: May 29, 2026, 11:57 p.m.

Read Full Article

Dostarlimab Plus Chemotherapy Yields Curative Potential in dMMR/MSI-H Endometrial Cancer - CancerNetwork

Dostarlimab Plus Chemotherapy Yields Curative Potential in dMMR/MSI-H Endometrial Cancer CancerNetwork

Published: May 29, 2026, 10:40 p.m.

Read Full Article

Dostarlimab Plus Chemotherapy Demonstrates Sustained Disease Control in dMMR/MSI-H Advanced Endometrial Cancer - HMP Global Learning Network

Dostarlimab Plus Chemotherapy Demonstrates Sustained Disease Control in dMMR/MSI-H Advanced Endometrial Cancer HMP Global Learning Network

Published: May 26, 2026, 4:46 p.m.

Read Full Article

Cadonilimab Plus Chemotherapy Shows Strong Efficacy and Safety in Advanced or Recurrent Endometrial Cancer - OncLive

Cadonilimab Plus Chemotherapy Shows Strong Efficacy and Safety in Advanced or Recurrent Endometrial Cancer OncLive

Published: April 12, 2026, 2:35 p.m.

Read Full Article

Neoadjuvant Chemotherapy Followed by Radical Cytoreductive Surgery in Serous Endometrial Carcinoma With Inguinal Lymph Node Metastasis: A Case Report - Cureus

Neoadjuvant Chemotherapy Followed by Radical Cytoreductive Surgery in Serous Endometrial Carcinoma With Inguinal Lymph Node Metastasis: A Case Report Cureus

Published: April 9, 2026, 9:38 a.m.

Read Full Article

Real-World Use of Dostarlimab Plus Chemotherapy in Advanced or Recurrent dMMR Endometrial Cancer - epi-phare

Real-World Use of Dostarlimab Plus Chemotherapy in Advanced or Recurrent dMMR Endometrial Cancer epi-phare

Published: March 9, 2026, 10:32 a.m.

Read Full Article

Endometrial cancer: AIFA approves immunotherapy with chemotherapy for all patients. - lamilano.it

Endometrial cancer: AIFA approves immunotherapy with chemotherapy for all patients. lamilano.it

Published: Feb. 23, 2026, 1:30 p.m.

Read Full Article

Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer - BioSpace

Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer BioSpace

Published: Feb. 4, 2026, 4:47 a.m.

Read Full Article

Latest Articles

NRG-GY018 at ASCO 2026: Pembrolizumab Plus Chemotherapy Sustains Overall Survival Benefit in Advanced Endometrial Cancer - Oncodaily

Pembrolizumab Plus Chemotherapy Shows Sustained Survival in Advanced EC - CancerNetwork

Pembrolizumab Plus Chemotherapy Shows Long-Term OS Benefit in Advanced/Recurrent Endometrial Cancer - OncLive

Dostarlimab Plus Chemotherapy Yields Curative Potential in dMMR/MSI-H Endometrial Cancer - CancerNetwork

Dostarlimab Plus Chemotherapy Demonstrates Sustained Disease Control in dMMR/MSI-H Advanced Endometrial Cancer - HMP Global Learning Network

Cadonilimab Plus Chemotherapy Shows Strong Efficacy and Safety in Advanced or Recurrent Endometrial Cancer - OncLive

Neoadjuvant Chemotherapy Followed by Radical Cytoreductive Surgery in Serous Endometrial Carcinoma With Inguinal Lymph Node Metastasis: A Case Report - Cureus

Real-World Use of Dostarlimab Plus Chemotherapy in Advanced or Recurrent dMMR Endometrial Cancer - epi-phare

Endometrial cancer: AIFA approves immunotherapy with chemotherapy for all patients. - lamilano.it

Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer - BioSpace

Subscribe to Our Newsletter